trending Market Intelligence /marketintelligence/en/news-insights/trending/sf0hkvlf1k_drmitdsaz5a2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Cardiome Pharma launches skin drug in Germany

South Korean Multichannel Industry To Survive With Right Strategies

South Korean Telcos Drive Next Wave Of Growth Through Home IoT Opportunities

Mining Exploration Insights: Financing Falls To 8-Month Low In October

Taking Advantage of Issuance Trends in 2020

Cardiome Pharma launches skin drug in Germany

Cardiome Pharma Corp. launched the Xydalba skin treatment ahead of schedule in Germany.

The drug is approved by the European Medicines Agency to treat adults with acute bacterial skin and skin structure infections, or ABSSSI. It has already been launched in the U.K.

The drug is planned for further launch in other European countries. The German ABSSSI hospital market is valued at $123 million, according to Datamonitor.